Ubs Group Ag Compass Therapeutics, Inc. Transaction History

Ubs Group Ag

$555 Billion
Q2 2025

A detailed history of Ubs Group Ag transactions in Compass Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 263,526 shares of CMPX stock, worth $1.02 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

263,526

Previous 152,851 72.41%

Holding current value

$1.02 Million

Previous $290,000 136.21%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$1.46 - $2.69 $161,585 - $297,715	110,675 Added 72.41%	263,526 $685,000
Q1 2025 May 13, 2025	SELL	$1.4 - $3.9 $15,126 - $42,139	-10,805 Reduced 6.6%	152,851 $290,000
Q4 2024 Feb 14, 2025	BUY	$1.35 - $1.98 $132,645 - $194,546	98,256 Added 150.24%	163,656 $237,000
Q3 2024 Nov 14, 2024	BUY	$0.8 - $1.88 $12,137 - $28,523	15,172 Added 30.21%	65,400 $120,000
Q2 2024 Aug 13, 2024	SELL	$1.0 - $1.85 $59,983 - $110,968	-59,983 Reduced 54.43%	50,228 $50,000
Q1 2024 May 13, 2024	BUY	$1.2 - $2.29 $9,195 - $17,548	7,663 Added 7.47%	110,211 $218,000
Q4 2023 Feb 09, 2024	BUY	$1.4 - $1.98 $60,904 - $86,135	43,503 Added 73.68%	102,548 $159,000
Q3 2023 Nov 09, 2023	SELL	$1.87 - $3.25 $6,389 - $11,105	-3,417 Reduced 5.47%	59,045 $116,000
Q2 2023 Aug 11, 2023	BUY	$2.64 - $3.48 $144,619 - $190,634	54,780 Added 713.1%	62,462 $198,000
Q1 2023 May 12, 2023	SELL	$3.14 - $5.48 $12,990 - $22,670	-4,137 Reduced 35.0%	7,682 $25,000
Q4 2022 Feb 08, 2023	BUY	$2.55 - $5.41 $11,707 - $24,837	4,591 Added 63.52%	11,819 $59,000
Q4 2021 Feb 14, 2022	BUY	$2.88 - $3.98 $20,816 - $28,767	7,228 New	7,228 $23,000

Others Institutions Holding CMPX

# of Institutions

103

Shares Held

101M

Call Options Held

18.2K

Put Options Held

2.51M

View Full List

About Compass Therapeutics, Inc.

Ticker CMPX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 101,285,000
Market Cap $393M
Description
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascula...

More about CMPX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account